Literature DB >> 9533259

Longitudinal models for AIDS marker data.

W J Boscardin1, J M Taylor, N Law.   

Abstract

Over the past decade, researchers have put a great amount of effort into developing suitable models for the analysis of longitudinal CD4 data and other markers of AIDS progression. These models must be general enough to allow for different patterns of change in the marker data. In this paper, we review the existing literature including our preferred models which involve mixed effects, stochastic terms and independent measurement error. Adding stochastic terms to standard mixed effects models gives an interpretable and parsimonious method for generalizing the covariance structure of the measurement error and short-term variability. We focus on univariate and bivariate models with integrated Ornstein-Uhlenbeck (IOU) stochastic terms. The IOU process allows for a range of biologically plausible derivative tracking that encompasses both random trajectory and Brownian motion behaviour. We illustrate these modelling techniques on longitudinal CD4 and viral RNA data.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9533259     DOI: 10.1177/096228029800700103

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  14 in total

1.  Assessing agreement in the timing of treatment initiation determined by repeated measurements of novel versus gold standard technologies with application to the monitoring of CD4 counts in HIV-infected patients.

Authors:  Farzad Noubary; Michael D Hughes
Journal:  Stat Med       Date:  2010-08-15       Impact factor: 2.373

2.  Continuous Time Nonstationary Correlation Models for Sparse Longitudinal Data.

Authors:  Vinay K Cheruvu; Jeffrey M Albert
Journal:  Model Assist Stat Appl       Date:  2019-07-18

3.  Long-term progression of viral load and serum markers of fibrosis among treated and untreated patients with chronic hepatitis B.

Authors:  Jia Li; Stuart C Gordon; Loralee B Rupp; Talan Zhang; Sheri Trudeau; Scott D Holmberg; Anne C Moorman; Philip R Spradling; Eyasu H Teshale; Joseph A Boscarino; Yihe G Daida; Mark A Schmidt; Mei Lu
Journal:  J Gastroenterol Hepatol       Date:  2017-06       Impact factor: 4.029

4.  Factors affecting timing of antiretroviral treatment initiation based on monitoring CD4 counts.

Authors:  Farzad Noubary; Michael D Hughes
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

5.  Efficient use of longitudinal CD4 counts and viral load measures in survival analysis.

Authors:  S E Holte; T W Randolph; J Ding; J Tien; R S McClelland; J M Baeten; J Overbaugh
Journal:  Stat Med       Date:  2012-03-13       Impact factor: 2.373

6.  Additive-Multiplicative Rates Model for Recurrent Event Data with Intermittently Observed Time-Dependent Covariates.

Authors:  Tianmeng Lyu; Xianghua Luo; Yifei Sun
Journal:  J Data Sci       Date:  2021-11-04

7.  Linear mixed models for multiple outcomes using extended multivariate skew-t distributions.

Authors:  Binbing Yu; A James O'Malley; Pulak Ghosh
Journal:  Stat Interface       Date:  2014       Impact factor: 0.582

8.  Clinical, immunological and virological evolution in patients with CD4 T-cell count above 500/mm3: is there a benefit to treat with highly active antiretroviral therapy (HAART)?

Authors:  Lionel Piroth; Christine Binquet; Marielle Buisson; Evelyne Kohli; Michel Duong; Michèle Grappin; Michal Abrahamowicz; Catherine Quantin; Henri Portier; Pascal Chavanet
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

9.  Bayesian semiparametric mixture Tobit models with left censoring, skewness, and covariate measurement errors.

Authors:  Getachew A Dagne; Yangxin Huang
Journal:  Stat Med       Date:  2013-04-02       Impact factor: 2.373

10.  Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapy.

Authors:  Thierry Buclin; Amalio Telenti; Rafael Perera; Chantal Csajka; Hansjakob Furrer; Jeffrey K Aronson; Paul P Glasziou
Journal:  PLoS One       Date:  2011-04-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.